CytomX/$CTMX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About CytomX
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
Ticker
$CTMX
Sector
Primary listing
Employees
120
Headquarters
Website
CytomX Metrics
BasicAdvanced
$318M
3.92
$0.49
2.13
-
Price and volume
Market cap
$318M
Beta
2.13
52-week high
$3.10
52-week low
$0.40
Average daily volume
3.5M
Financial strength
Current ratio
4.197
Quick ratio
4.078
Long term debt to equity
1.203
Total debt to equity
5.742
Profitability
EBITDA (TTM)
44.7
Gross margin (TTM)
100.00%
Net profit margin (TTM)
34.01%
Operating margin (TTM)
30.56%
Effective tax rate (TTM)
0.52%
Revenue per employee (TTM)
$1,180,000
Management effectiveness
Return on assets (TTM)
16.13%
Return on equity (TTM)
108.21%
Valuation
Price to earnings (TTM)
3.921
Price to revenue (TTM)
1.324
Price to book
2.65
Price to tangible book (TTM)
2.69
Price to free cash flow (TTM)
-2.406
Free cash flow yield (TTM)
-41.57%
Free cash flow per share (TTM)
-0.802
Growth
Revenue change (TTM)
18.01%
Earnings per share change (TTM)
265.60%
3-year revenue growth (CAGR)
73.65%
10-year revenue growth (CAGR)
34.00%
3-year earnings per share growth (CAGR)
-39.25%
10-year earnings per share growth (CAGR)
-32.69%
What the Analysts think about CytomX
Analyst ratings (Buy, Hold, Sell) for CytomX stock.
Bulls say / Bears say
Released promising interim Phase 1 results for CX-2051 in advanced colorectal cancer, reporting a 28% confirmed response rate and no dose-limiting toxicities as of April 7, 2025, supporting early signs of efficacy and safety – (Nasdaq)
Successfully completed a $100 million underwritten stock offering in May 2025, raising approximately $93.4 million net and ending Q2 2025 with $158.1 million in cash and investments, extending its runway to Q2 2027 – (CytomX IR)
Cut total operating expenses by $13.7 million year-over-year to $19.9 million in Q2 2025 from $33.6 million in Q2 2024, showing disciplined capital management – (CytomX IR)
Total revenue fell by 25.5% year-over-year to $18.7 million in Q2 2025 from $25.1 million in Q2 2024, reflecting the end of partnership commitments and program deprioritization, which could limit future growth – (CytomX IR)
CytomX’s PROBODY® platform has yet to prove itself in late-stage trials, and company filings caution that limited knowledge of its pharmacology and immunogenicity may hinder development and commercialization – (SEC)
A treatment-related Grade 5 acute kidney injury was observed in the CX-2051 Phase 1 study, raising serious safety concerns that could hold back the program and impact regulatory approvals – (Stock Titan)
Data summarised monthly by Lightyear AI. Last updated on 7 Sept 2025.
CytomX Financial Performance
Revenues and expenses
CytomX Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for CytomX stock?
CytomX (CTMX) has a market cap of $318M as of September 19, 2025.
What is the P/E ratio for CytomX stock?
The price to earnings (P/E) ratio for CytomX (CTMX) stock is 3.92 as of September 19, 2025.
Does CytomX stock pay dividends?
No, CytomX (CTMX) stock does not pay dividends to its shareholders as of September 19, 2025.
When is the next CytomX dividend payment date?
CytomX (CTMX) stock does not pay dividends to its shareholders.
What is the beta indicator for CytomX?
CytomX (CTMX) has a beta rating of 2.13. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.